StudyFinder
A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)
Status: Recruiting
The purpose of this research study is to look at the safety and effectiveness of pritelivir given orally (by mouth for a maximum of 42 days) for people with an impaired immune system who have recurrent lesions caused by the form of HSV that does respond to treatment with acyclovir.
Sex: Male or Female
Age Group: Not specified
Inclusion Criteria:
• at least 16 years old
• immunocompromised or body is unable to fight off infection
• have lesions that can been seen in order to determine if they are healing
• willing to use highly effective birth control
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:
• history or current evidence of gastrointestinal malabsorption
• on hemodialysis for any reason and end stage renal disease (ESRD)
• women who are pregnant or breastfeeding
• unable to communicate with study staff
Conditions:
Rare Diseases, Infectious Diseases
Keywords:
Clinics and Surgery Center (CSC), Herpes, Herpes Simplex Virus, HSV Infection
Study Contact: Natalie Eichten - eicht024@umn.edu
Principal Investigator: Jo-Anne Young, MD
Phase: PHASE3
IRB Number: STUDY00020605
See this study on ClinicalTrials.gov